LP
ONCT

LMR Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

LMR Partners’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-789
Closed -$14K – 1364
2022
Q3 		$14K Hold
789
– – ﹤0.01% 1179
2022
Q2 		$18K Buy
+789
New +$17.6K ﹤0.01% 1240
2014
Q3 		– Sell
-41
Closed -$78K – 501
2014
Q2 		$78K Buy
+41
New +$81.1K 0.01% 445

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LMR Partners's ONCT Position: Q4 2022 in Review

LMR Partners sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2022, closing a stake of 789 shares — an estimated $14K sold.

LMR Partners first reported a position in ONCT in Q2 2014 and held it in 3 quarters. The position peaked at $78K in Q2 2014. 58 funds tracked by Wall St. Rank hold ONCT as of Q4 2022.

  • LMR Partners reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 789 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $14K.
  • LMR Partners first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2014 and held it in 3 quarters.
  • LMR Partners's Oncternal Therapeutics, Inc. Common Stock position peaked at $78K in Q2 2014.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.